对于侵袭性淋巴瘤患者, 罗氏新药Columvi治疗显示生存率提高了40%. New Roche treatment Columvi shows 40% better survival rate for aggressive lymphoma patients.

Roche's Columvi是治疗复发性或易碎性扩散的大型B细胞淋巴瘤(DLBCL)的新疗法,在一项为期两年的后续研究中显示总体存活率提高了40%。 Roche's Columvi, a new treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), showed a 40% improvement in overall survival in a two-year follow-up study. 与接受标准疗法治疗的病人相比,结合其他药物接受Columvi的病人的存活率较好。 Patients who received Columvi in combination with other drugs had better survival rates compared to those treated with a standard regimen. 虽然与Columvi相比,不良事件更为常见,但这种治疗为具有攻击性的淋巴瘤病例提供了一个很有希望的现成选择。 While adverse events were more common with Columvi, the treatment offers a promising off-the-shelf option for aggressive lymphoma cases.